Macro “Risk On”: Life Science Stock Follow Up 3.4%
Rayno Life Science Portfolios Up 3.4% Two big up days this week were driven primarily by high expectations by Central Bank coordination to cut the cost of emergency dollar funding and news from the People's Bank of China to cut the reserve ratio.US economic data was also positive with private...
Rayno Life Science Portfolios Run With NASDAQ Up 3.79%
Life Science Stocks Have a Big Day The Rayno Biopharmaceutical Portfolio was up over 3.7% today as all biotechnology stocks pretty much tracked NASDAQ which was up 3.5%. Although we remain cautious with no new buys we have a good chance for a Q4 rally as the sector is outperforming NASDAQ...
Gilead (GILD) $11B Deal for Pharmasset (VRUS) Sparks Biotech Stocks
Pharmasset Buyout Brings To Mind M&A Upside for Biotech Stocks: ETF's and Funds Lead the Way Gilead (GILD $35) stepped up with a huge buyout of Pharmasset (VRUS $134.21) driving the stock up 89% over Fridays' close and 519% YTD! Pharmasset has no revenues but has a three potential...
Caution on Biotechs With Risk Off Situation-UPDATE 1/5/12 Dendreon Soars
Dendreon (DNDN $10.94) soared 44% today on a business update saying Provenge sales for its prostate cancer treatment were better than expected. Fourth quarter gross revenues were $82M with full year revenues at $228M .Also the Center for Medicare and Medicaid Services updated their...
Fidelity Biotech Fund (FBIOX) up 7.9% YTD Outperforms Major ETFs
Managed Healthcare Mutual Funds Starting To OutPerform ETFs Earlier this year we wrote an article on Investor Uprising comparing returns on biotech funds and major ETFs. At the time ETF's were outperforming managed mutual funds. Now as we enter the strong quarter for small cap and biotech...